New York, May 21, 2026, 04:17 EDT
RxSight Inc. (Nasdaq: RXST) trades higher Thursday morning. The ophthalmic device stock finished at $6.160 on Wednesday, a gain of 3.53%. Even with that bounce, shares are down 40.88% year-to-date.
Execution is the key test in the near term, not launching something new. RxSight said management will join a fireside chat at the Stifel 2026 Virtual Ophthalmology Forum on May 26. The event gives investors a set time to see if the company’s sales reset has momentum.
The report arrives in Nasdaq’s pre-market, ahead of the 9:30 a.m. ET open. Nasdaq says May 21 isn’t a market holiday in its 2026 calendar. Memorial Day, May 25, is the next closure.
RxSight makes a cataract-surgery system using its Light Adjustable Lens, or LAL, which is an implant that doctors can fine-tune after surgery with the company’s Light Delivery Device, or LDD.
Strain is still showing in RxSight’s first quarter. The company booked $30.9 million in sales, down 18.5% from last year, with 27,472 LAL units and 20 LDDs sold. RxSight kept its 2026 sales forecast in place at $120 million to $135 million. CEO Ron Kurtz said management is “encouraged by the stabilizing business trends” and sees “initial progress” from recent commercial moves. GlobeNewswire
LAL procedures brought in around $27 million, making up 88% of RxSight’s Q1 sales, CFO Mark Wilterding said on the May 6 earnings call. CEO Kurtz said the business “appears to be stabilizing.” Wilterding added that RxSight was spending to back “sustainable growth and profitability.” Investing
Stocks moved higher again Wednesday. The S&P 500 gained 1.08%, and the Nasdaq Composite climbed 1.55% as technology and chip names rallied before Nvidia’s numbers. Wall Street’s major indexes got a lift from the broader tape.
But the risks are still clear. The intraocular lens market has a lot of competition, with RxSight listing Alcon, Johnson & Johnson, and Bausch + Lomb as main competitors. The company’s filing also notes growth could slow if doctors avoid using the system, practices push back on the LDD’s upfront price, or patients don’t want more clinic trips and higher out-of-pocket costs.
RXST’s next stop is the May 26 webcast. Investors are expected to tune in for updates on device placements, how much LAL is being used at current practices, and any color on progress overseas. They also want to know if management is finding the full-year guidance tougher or easier to stand by.
